CJC-1295 (2 mg)

Long-acting GHRH Analog / DAC-Modified Growth Hormone Secretagogue

CJC-1295 is a synthetic tetrasubstituted analog of Growth Hormone–Releasing Hormone (GHRH 1-29) designed to dramatically extend the peptide’s half-life and biological activity. The peptide is engineered in two forms:

• CJC-1295 with DAC (Drug Affinity Complex): binds covalently to albumin → very long half-life

• CJC-1295 (MOD-GRF 1-29): shorter-acting, but more stable than native GHRH

In research settings, “CJC-1295” typically refers to the DAC form, which produces sustained GH release, elevated IGF-1 levels, and prolonged endocrine signaling.

CJC-1295 is widely used to study:

• GH/IGF-1 axis physiology

• Metabolic function & lipolysis models

• Muscle anabolism & recovery biology

• Aging, regeneration & mitochondrial function

• Sleep-related GH rhythmicity

• Endocrine feedback mechanisms

CJC-1295 (2 mg) provided as lyophilized powder is strictly for research use only.

Specifications

Synonyms: CJC-1295, CJC-1295 DAC, MOD-GRF 1-29 (non-DAC form), GHRH analog
Sequence: Modified GHRH(1-29) with four amino-acid substitutions + reactive maleimide group for albumin binding (DAC form)
Molecular Formula (DAC): ~C165H269N47O46
Molecular Weight (DAC): ~3367 Da (approx., depending on conjugation state)
Class: Long-acting GHRH analog / GH secretagogue
Presentation: 2 mg lyophilized peptide, ≥98% purity, research grade

Mechanism of Action and Endocrine Pathways

CJC-1295 functions as a selective agonist at the GHRH receptor (GHRH-R) located on pituitary somatotroph cells.

1. GHRH receptor activation

Binding triggers:

• ↑ cAMP

• ↑ Protein kinase A (PKA)

• ↑ GH gene transcription

• ↑ Pulsatile GH secretion

2. DAC modification → prolonged half-life

The DAC (Drug Affinity Complex) component:

• Covalently binds to serum albumin

• Protects against enzymatic degradation

• Extends half-life from minutes → days

• Allows sustained GH release without continuous dosing

3. Increased IGF-1

GH stimulation leads to:

• Hepatic IGF-1 production

• IGF-1–mediated tissue growth, repair, metabolism modulation

4. Preserved physiologic GH pulsatility

Unlike direct GH administration, CJC-1295:

• Enhances natural GH pulses

• Avoids suppression of GH negative feedback pathways

• Allows circadian rhythm–dependent secretion

Metabolic, Body Composition and Endocrine Research

1. Reduction of adiposity

Studies show GHRH analogs (including CJC-1295) stimulate:

• Lipolysis via GH activation

• Fatty acid mobilization

• Visceral fat reduction in GH-deficient or suppressed models

2. Improved protein synthesis and muscle recovery

GH/IGF-1 axis activation supports:

• Muscle repair

• Nitrogen retention

• Enhanced collagen synthesis

• Increased lean body mass (context-dependent)

3. Enhanced mitochondrial and metabolic function

CJC-1295-induced GH signaling is linked to:

• ↑ Mitochondrial biogenesis

• ↑ ATP production

• Improved cellular recovery from oxidative stress

4. Sleep and circadian GH research

GH secretion naturally peaks during slow-wave sleep.
CJC-1295 is used experimentally to study:

• GH-linked sleep architecture

• Age-related decline in GH pulses

• Neuroendocrine recovery models

Cellular and Genetic Research Applications

CJC-1295 effects extend to:

1. Gene transcription modulation

GH/IGF-1 signaling regulates genes related to:

• Muscle hypertrophy (e.g., MyoD, myogenin)

• Lipid metabolism

• Fibroblast proliferation and repair

• Hepatic metabolism

2. Tissue regeneration models

Research demonstrates improved:

• Fibroblast growth

• Collagen deposition

• Tendon and cartilage repair

• Skin and connective tissue integrity

3. Anti-inflammatory signaling

GH and IGF-1 pathways can reduce:

• TNF-α

• IL-6

• CRP (context-dependent research findings)

DAC vs. Non-DAC CJC-1295

The 2 mg product described here refers to the DAC version unless specified otherwise.

Safety, Limitations, and Regulatory Notes

• CJC-1295 is not approved by FDA, EMA, or other major regulators for therapeutic use.

• Research-grade peptide may differ from pharmaceutical-grade preparations used in some clinical trials.

• Potential GH/IGF-1–related physiological effects (not applicable to research use): edema, arthralgia, insulin sensitivity shifts, carpal tunnel–like symptoms (reported in GH studies).

• Should not be used for bodybuilding, anti-aging, or unregulated hormone manipulation.

Research Use Only – Important Notice

This CJC-1295 (2 mg) product is supplied exclusively for laboratory research.

• Not for human or veterinary use

• Not for therapeutic, anabolic, metabolic, anti-aging, or diagnostic application

• Intended only for controlled in vitro studies and animal research

• All descriptions summarize findings from preclinical and endocrine research

• Not to be interpreted as medical or dosing advice

References (Non-Wikipedia, peer-reviewed, with links)

1. Teichman SL et al. CJC-1295, a long-acting growth hormone–releasing hormone analog: pharmacokinetics and pharmacodynamics. J Clin Endocrinol Metab.
   https://pubmed.ncbi.nlm.nih.gov/16478781/

Ionescu M et al. Sustained GH and IGF-1 elevation following CJC-1295 administration. J Clin Endocrinol Metab.
https://pubmed.ncbi.nlm.nih.gov/16263830/

Walker RF. Advances in GHRH analog design: stability, receptor affinity, and endocrine effects. Endocrine.
https://pubmed.ncbi.nlm.nih.gov/15700636/

Veldhuis JD et al. Pulsatile GH secretion and the role of GHRH analogs. Endocr Rev.
https://pubmed.ncbi.nlm.nih.gov/12153750/

Nass R, Thorner MO. GH/IGF-1 axis and metabolic homeostasis. Endocr Pract.
https://pubmed.ncbi.nlm.nih.gov/12511902/

Laron Z. GH and IGF-1 in tissue regeneration and metabolic research. Mol Cell Endocrinol.
https://pubmed.ncbi.nlm.nih.gov/16828482/